Figure 3

Kaplan-Meier survival analyses of patients with pancreatic ductal adenocarcinomas (PDACs) according to mutations in the BRCA pathway genes. Nine patients with PDACs with potentially deleterious mutations in BRCA pathway genes, namely, BRCA1, BRCA2 and PALB2 (Mutant), and 33 patients with PDACs with benign mutations or without mutations in the BRCA pathway genes (Benign or wild) were compared. The P value was obtained by Log-rank test.